BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clinical Immunology 2021;226:108707. [DOI: 10.1016/j.clim.2021.108707] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 42.0] [Reference Citation Analysis]
Number Citing Articles
1 Mark J, Fisher DT, Kim M, Emmons T, Khan AN, Alqassim E, Singel K, Mistarz A, Lugade A, Zhan H, Yu H, Segal B, Lele S, Frederick P, Kozbor D, Skitzki J, Odunsi K. Carboplatin enhances lymphocyte-endothelial interactions to promote CD8+ T cell trafficking into the ovarian tumor microenvironment. Gynecologic Oncology 2023;168:92-99. [DOI: 10.1016/j.ygyno.2022.11.001] [Reference Citation Analysis]
2 Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
3 Mortezaee K, Majidpoor J, Najafi S. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. Life Sciences 2022;310:121083. [DOI: 10.1016/j.lfs.2022.121083] [Reference Citation Analysis]
4 He R, Yuan X, Chen Z, Zheng Y. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. International Immunopharmacology 2022;113:109444. [DOI: 10.1016/j.intimp.2022.109444] [Reference Citation Analysis]
5 Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy 2022;156:113906. [DOI: 10.1016/j.biopha.2022.113906] [Reference Citation Analysis]
6 Mortezaee K, Majidpoor J. Cellular immune states in SARS-CoV-2-induced disease. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1016304] [Reference Citation Analysis]
7 Yu J, Yin Y, Yu Y, Cheng M, Zhang S, Jiang S, Dong M. Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs. Immunopharmacology and Immunotoxicology 2022. [DOI: 10.1080/08923973.2022.2145966] [Reference Citation Analysis]
8 Wang G, Liu Y, Liu S, Lin Y, Hu C. Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. Int J Mol Sci 2022;23:12647. [PMID: 36293504 DOI: 10.3390/ijms232012647] [Reference Citation Analysis]
9 Mortezaee K, Majidpoor J. Extracellular vesicle-based checkpoint regulation and immune state in cancer. Med Oncol 2022;39:225. [PMID: 36175741 DOI: 10.1007/s12032-022-01837-2] [Reference Citation Analysis]
10 Nief CA, Swartz AM, Chelales E, Sheu LY, Crouch BT, Ramanujam N, Nair SK. Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. Cancers 2022;14:4669. [DOI: 10.3390/cancers14194669] [Reference Citation Analysis]
11 Mortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol 2022;39:193. [PMID: 36071302 DOI: 10.1007/s12032-022-01801-0] [Reference Citation Analysis]
12 Gautam SK, Basu S, Aithal A, Dwivedi NV, Gulati M, Jain M. Regulation of pancreatic cancer therapy resistance by chemokines. Semin Cancer Biol 2022:S1044-579X(22)00196-1. [PMID: 36064086 DOI: 10.1016/j.semcancer.2022.08.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Wu S, Lv X, Li Y, Gao X, Ma Z, Fu X, Li Y, Zhang Z. Integrated Machine Learning and Single-Sample Gene Set Enrichment Analysis Identifies a TGF-Beta Signaling Pathway Derived Score in Headneck Squamous Cell Carcinoma. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/3140263] [Reference Citation Analysis]
14 Deng H, Wang L, Wang N, Zhang K, Zhao Y, Qiu P, Qi X, Zhang D, Xu F, Liu J. Neoadjuvant Checkpoint Blockade in Combination with Chemotherapy in Patients with Tripe-Negative Breast Cancer: Exploratory Analysis of Real-World, Multicenter Data.. [DOI: 10.21203/rs.3.rs-1941236/v1] [Reference Citation Analysis]
15 Pleiko K, Haugas M, Parfejevs V, Pantelejevs T, Parisini E, Teesalu T, Riekstina U. Targeting triple-negative breast cancer with β1-integrin binding aptamer.. [DOI: 10.1101/2022.07.28.501822] [Reference Citation Analysis]
16 Mortezaee K, Majidpoor J. Dysregulated metabolism: A friend-to-foe skewer of macrophages. International Reviews of Immunology. [DOI: 10.1080/08830185.2022.2095374] [Reference Citation Analysis]
17 Zhang Y, Cui Q, Xu M, Liu D, Yao S, Chen M. Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. Front Immunol 2022;13:901772. [DOI: 10.3389/fimmu.2022.901772] [Reference Citation Analysis]
18 Wang X, Zhu X, Li B, Wei X, Chen Y, Zhang Y, Wang Y, Zhang W, Liu S, Liu Z, Zhai W, Zhu P, Gao Y, Chen Z. Intelligent Biomimetic Nanoplatform for Systemic Treatment of Metastatic Triple-Negative Breast Cancer via Enhanced EGFR-Targeted Therapy and Immunotherapy. ACS Appl Mater Interfaces 2022. [PMID: 35549005 DOI: 10.1021/acsami.2c02925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Hung YH, Chen LT, Hung WC. The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy. Biomedicines 2022;10:926. [PMID: 35453676 DOI: 10.3390/biomedicines10040926] [Reference Citation Analysis]
20 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers (Basel) 2022;14:1710. [PMID: 35406483 DOI: 10.3390/cancers14071710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mortezaee K, Majidpoor J. Checkpoint inhibitor/interleukin-based combination therapy of cancer. Cancer Med 2022. [PMID: 35301813 DOI: 10.1002/cam4.4659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
24 Pomponio R, Tang Q, Mei A, Caron A, Coulibaly B, Theilhaber J, Rogers-grazado M, Sanicola-nadel M, Naimi S, Olfati-saber R, Combeau C, Pollard J, Lin TT, Wang R. An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGFβ blockade therapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.03.013] [Reference Citation Analysis]
25 Yu S, Wang Y, He P, Shao B, Liu F, Xiang Z, Yang T, Zeng Y, He T, Ma J, Wang X, Liu L. Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. Front Oncol 2022;12:809304. [DOI: 10.3389/fonc.2022.809304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Yu DL, Lou ZP, Ma FY, Najafi M. The interactions of paclitaxel with tumour microenvironment. Int Immunopharmacol 2022;105:108555. [PMID: 35121223 DOI: 10.1016/j.intimp.2022.108555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
27 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
28 Tian W, Lei N, Zhou J, Chen M, Guo R, Qin B, Li Y, Chang L. Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death Dis 2022;13:64. [PMID: 35042862 DOI: 10.1038/s41419-022-04510-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
29 韩 娜. Immune Checkpoint Inhibitor Combination Therapy for Stage IV Pancreatic Cancer in 1 Case and Literature Review. ACM 2022;12:10299-10303. [DOI: 10.12677/acm.2022.12111485] [Reference Citation Analysis]
30 Silvestris N, Argentiero A, Brunetti O, Sonnessa M, Colonna F, Delcuratolo S, Luchini C, Scarpa A, Lonardi S, Nappo F, Fassan M, Solimando AG, Fucci L, Saponaro C. PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. Expert Opin Ther Targets 2021;:1-10. [PMID: 34846251 DOI: 10.1080/14728222.2021.2011859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Karin N. Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones? Cancers (Basel) 2021;13:6317. [PMID: 34944943 DOI: 10.3390/cancers13246317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
32 Waters CM. Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy. Open Biol 2021;11:210277. [PMID: 34905701 DOI: 10.1098/rsob.210277] [Reference Citation Analysis]
33 Papp O, Doma V, Gil J, Markó-Varga G, Kárpáti S, Tímár J, Vízkeleti L. Organ Specific Copy Number Variations in Visceral Metastases of Human Melanoma. Cancers (Basel) 2021;13:5984. [PMID: 34885093 DOI: 10.3390/cancers13235984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Mortezaee K, Majidpoor J. Key promoters of tumor hallmarks. Int J Clin Oncol 2021. [PMID: 34773527 DOI: 10.1007/s10147-021-02074-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
35 Majidpoor J, Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomed Pharmacother 2021;145:112419. [PMID: 34781146 DOI: 10.1016/j.biopha.2021.112419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
36 Song Q, Javid A, Zhang G, Li Y. Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives. Front Immunol 2021;12:701485. [PMID: 34675914 DOI: 10.3389/fimmu.2021.701485] [Reference Citation Analysis]
37 Li Y, Wang J, Wang F, Gao C, Cao Y, Wang J. Development and Verification of an Autophagy-Related lncRNA Signature to Predict Clinical Outcomes and Therapeutic Responses in Ovarian Cancer. Front Med (Lausanne) 2021;8:715250. [PMID: 34671615 DOI: 10.3389/fmed.2021.715250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Yang Z, Deng Y, Cheng J, Wei S, Luo H, Liu L. Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers. Front Oncol 2021;11:695006. [PMID: 34604032 DOI: 10.3389/fonc.2021.695006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Li Q, Xiao M, Shi Y, Hu J, Bi T, Wang C, Yan L, Li X. eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1. BMC Cancer 2021;21:1022. [PMID: 34525951 DOI: 10.1186/s12885-021-08749-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
41 Sun BL. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment. Prostate 2021;81:1125-34. [PMID: 34435699 DOI: 10.1002/pros.24213] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
42 Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S, Reni M. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Cancer Treat Rev 2021;100:102262. [PMID: 34418781 DOI: 10.1016/j.ctrv.2021.102262] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
43 Švajger U, Tešić N, Rožman P. Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ. Int Immunopharmacol 2021;99:107978. [PMID: 34298399 DOI: 10.1016/j.intimp.2021.107978] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
44 Mortezaee K. Normalization in tumor ecosystem: Opportunities and challenges. Cell Biol Int 2021. [PMID: 34189798 DOI: 10.1002/cbin.11655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
45 Antognelli C, Mandarano M, Prosperi E, Sidoni A, Talesa VN. Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. Cancers (Basel) 2021;13:2965. [PMID: 34199263 DOI: 10.3390/cancers13122965] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
46 Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. [PMID: 34004256 DOI: 10.1016/j.lfs.2021.119627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
47 Du Z, Niu S, Wang J, Wu J, Li S, Yi X. SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis. Autoimmunity 2021;54:225-33. [PMID: 33904361 DOI: 10.1080/08916934.2021.1913582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
48 Zhang T, Zheng S, Liu Y, Li X, Wu J, Sun Y, Liu G. DNA damage response and PD-1/PD-L1 pathway in ovarian cancer. DNA Repair (Amst) 2021;102:103112. [PMID: 33838550 DOI: 10.1016/j.dnarep.2021.103112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]